Xcout IntelObsidian Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Obsidian Therapeutics, Inc. among biotech companies — ranked by similarity to what Obsidian Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Obsidian Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Obsidian Therapeutics, Inc.
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
Obsidian Therapeutics, Inc. at a glance
Obsidian Therapeutics, Inc. is a biotech company headquartered in Cambridge, United States. It is publicly listed (OBX) with a market capitalisation of $13.5M. Xcout tracks 13 named people at Obsidian Therapeutics, Inc., including Madan Jagasia (President, CEO & Director). Xcout recorded 33 job postings from Obsidian Therapeutics, Inc. in the last 90 days, naming tools such as ADP, NetSuite, SAP.
Obsidian Therapeutics, Inc. leadership
- Madan JagasiaPresident, CEO & Director
- Julie FederChief Financial Officer
- Dana AlexanderChief Technical Officer
- Parameswaran HariChief Medical Officer
- Jennifer H. PetersonChief People Officer
- Maria FardisExecutive Chairman of the Board
7 more named people on record for Obsidian Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Obsidian Therapeutics, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $160.5M | 13 named | |
| — | $115M | — | |
| Series A | $49.5M | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Obsidian Therapeutics, Inc.
Xcout recorded 33 job postings from Obsidian Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since July 2026.
Tools named in Obsidian Therapeutics, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see Obsidian Therapeutics, Inc.'s hiring signals →
Recent Obsidian Therapeutics, Inc. news
8 corporate events on record, with sources — see the full timeline →
Top 12 Obsidian Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Obsidian Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.
Biotechnology
Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative technology platforms and first-in-class T-cell therapies to access cancer-specific targets.
Similar biotech company
ArsenalBio is a biotechnology company developing programmable cell therapies, particularly engineered T-cell therapies, for cancer treatment. It serves biopharmaceutical and healthcare markets by using synthetic biology and genomic engineering to create more effective, controllable immune-cell medicines.
Similar biotech company
Kite Pharma is a biopharmaceutical company that develops and manufactures custom CAR T-cell therapies to treat certain types of blood cancer. The company utilizes patients' own engineered immune cells to target and attack cancer, serving patients diagnosed with conditions such as lymphomas.
Similar biotech company
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Biotechnology
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.
Biotechnology
Salspera, Inc. is a biopharmaceutical company that develops genetically engineered microbial immunotherapies designed to treat solid tumors. Its lead candidate, Saltikva, uses synthetic biology to target tumors and activate the body's natural killer cells while aiming to minimize toxicity and enhance the effects of traditional chemotherapy.
Biotechnology
CytoImmune Therapeutics, Inc. is a biotechnology company headquartered in Duarte, California, focused on the development of novel cancer immunotherapy treatments.
Biotechnology
Avammune Therapeutics is an R&D-driven drug discovery company headquartered in Philadelphia, Pennsylvania. The company focuses on developing novel, modality-agnostic immunotherapies and cancer therapies to address high unmet medical needs in hard-to-treat solid tumors.
Biotechnology
BrainChild Bio is a clinical-stage biotechnology company that develops CAR-T cell therapies to treat tumors in the central nervous system (CNS). The company prioritizes pediatric patients with brain tumors while also extending its technology platform to address adult indications such as glioblastoma and brain metastases.
Biotechnology
Revolution Medicines is a clinical-stage oncology company that develops novel targeted therapies to outsmart cancer. The company focuses on discovering and advancing therapeutic pipelines for patients with difficult-to-treat tumors.
Biotechnology
Context Therapeutics Inc. is a biopharmaceutical company headquartered in Philadelphia, Pennsylvania. It is committed to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibodies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Obsidian Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Obsidian Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →